Abpro Holdings, Inc. (ABP)

NASDAQ: ABP · Real-Time Price · USD
0.2130
-0.0230 (-9.75%)
At close: Jun 24, 2025, 4:00 PM
0.2137
+0.0007 (0.33%)
After-hours: Jun 24, 2025, 7:59 PM EDT
-9.75%
Market Cap 12.95M
Revenue (ttm) 183,000
Net Income (ttm) -21.61M
Shares Out 60.79M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,072,171
Open 0.2224
Previous Close 0.2360
Day's Range 0.2100 - 0.2261
52-Week Range 0.1516 - 11.1900
Beta -0.04
Analysts Strong Buy
Price Target 4.00 (+1,777.93%)
Earnings Date Aug 18, 2025

About ABP

Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company’s lead product candid... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2004
Employees 15
Stock Exchange NASDAQ
Ticker Symbol ABP
Full Company Profile

Financial Performance

In 2024, Abpro Holdings's revenue was $183,000, an increase of 50.00% compared to the previous year's $122,000. Losses were -$17.41 million, 48.7% more than in 2023.

Financial Statements

Analyst Forecast

According to one analyst, the rating for ABP stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(1,777.93% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...

2 months ago - GlobeNewsWire

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...

3 months ago - GlobeNewsWire

Abpro Statement on the Departure of Former CEO Ian Chan

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-thr...

3 months ago - GlobeNewsWire

Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing

WOBURN, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) (“Abpro”), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening di...

6 months ago - GlobeNewsWire